Ipca Laboratories Ltd
IPCALAB
Company Profile
Business description
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
Contact
No. 48, 123 AB, 125 & 126 Kandivli Industrial Estate
Kandivli (West)
MumbaiMH400067
INDT: +91 2262105000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
23,236
Stocks News & Analysis
stocks
Unconventional wisdom: A modern day bank run
Is the economy and investor portfolios at risk from a potential a ‘bank run’ in private credit?
stocks
Shares leap for ASX rare earths provider
We increased our fair value based on higher expected rare earths pricing.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,851.40 | 29.00 | -0.33% |
| CAC 40 | 7,984.44 | 72.92 | -0.91% |
| DAX 40 | 23,589.65 | 50.38 | -0.21% |
| Dow JONES (US) | 46,677.85 | 739.42 | -1.56% |
| FTSE 100 | 10,305.15 | 48.62 | -0.47% |
| HKSE | 25,716.76 | 182.00 | -0.70% |
| NASDAQ | 22,311.98 | 404.16 | -1.78% |
| Nikkei 225 | 54,452.96 | 572.41 | -1.04% |
| NZX 50 Index | 13,113.75 | 85.54 | -0.65% |
| S&P 500 | 6,672.62 | 103.18 | -1.52% |
| S&P/ASX 200 | 8,629.00 | 14.20 | -0.16% |
| SSE Composite Index | 4,129.10 | 4.33 | -0.10% |